Onswik (insulin efsitora alfa-gobe)
Eli Lilly (LLY)
ApprovedSep 23, 2026
Marketer take
Lilly's once-weekly basal insulin arrives six months after Novo Nordisk's Awiqli, setting up a direct weekly-insulin positioning fight in endocrinology and primary care where formulary placement decides early share.
- Sponsor company
- Eli Lilly (LLY)
- Indication
- To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise
- Therapeutic area
- Diabetes, Metabolic
- Event
- FDA approval
- Date
- Sep 23, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?